SLE (n=349) | Healthy controls (n=108) | ||||
aU/mL | n, % positive | aU/mL | n, % positive | Median difference (95% CI) | |
Anti-MAA | 35 (23–52)* | 101 (29) | 23 (18–29) | 3 (3) | 12 (7 to18) |
Anti-AGE | 112 (51–200)* | 63 (18) | 80 (41–122) | 4 (4) | 32 (3 to 60) |
Anti-CarP | 126 (50–206)* | 49 (14) | 35 (0–111) | 5 (5) | 91 (60 to 123) |
Anti-Cit | 3 (2–6) | 22 (6) | 3 (2 – 6) | 3 (3) | 0 (–1 to 1) |
Anti-AL | 8 (0–23) | 29 (8) | 4 (0–19) | 8 (7) | 4 (–2 to 9) |
Anti-NT | 44 (0–177) | 17 (5) | 11 (0–132) | 8 (7) | 33 (–1 to 67) |
Results are presented as n (%) or median (IQR).
*Statistically significant difference between patients with SLE and healthy controls (p≤0.0001).
AGE, advanced glycation end-product; AL, acetylated protein; aU/mL, arbitrary units per millilitre; CarP, carbamylated protein; Cit, citrullinated protein; MAA, malondialdehyde–acetaldehyde adduct; NT, nitrated protein.